Squarepoint
TBPH icon

Squarepoint’s Theravance Biopharma TBPH Stock Holding History

Squarepoint’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Buy
+17,762
New +$294K ﹤0.01% 3800
2026
Q1 		– Sell
-67,355
Closed -$1.26M – 4953
2025
Q4 		$1.26M Buy
67,355
+20,605
+44% +$342K ﹤0.01% 2410
2025
Q3 		$683K Buy
46,750
+33,428
+251% +$422K ﹤0.01% 2970
2025
Q2 		$147K Sell
13,322
-10,445
-44% -$102K ﹤0.01% 4068
2025
Q1 		$212K Sell
23,767
-23,401
-50% -$218K ﹤0.01% 3977
2024
Q4 		$444K Sell
47,168
-51,783
-52% -$471K ﹤0.01% 3826
2024
Q3 		$798K Sell
98,951
-17,305
-15% -$150K ﹤0.01% 2776
2024
Q2 		$986K Buy
+116,256
New +$1.05M ﹤0.01% 2567
2024
Q1 		– Sell
-52,054
Closed -$585K – 4598
2023
Q4 		$585K Buy
+52,054
New +$524K ﹤0.01% 2890
2023
Q3 		– Sell
-48,706
Closed -$504K – 4232
2023
Q2 		$504K Sell
48,706
-1,070
-2% -$11.8K ﹤0.01% 2616
2023
Q1 		$540K Sell
49,776
-18,503
-27% -$196K ﹤0.01% 2256
2022
Q4 		$766K Buy
68,279
+13,553
+25% +$142K ﹤0.01% 2015
2022
Q3 		$555K Buy
54,726
+35,741
+188% +$335K ﹤0.01% 2154
2022
Q2 		$172K Buy
+18,985
New +$175K ﹤0.01% 2519
2022
Q1 		– Sell
-15,971
Closed -$176K – 3503
2021
Q4 		$176K Sell
15,971
-19,255
-55% -$168K ﹤0.01% 2757
2021
Q3 		$261K Buy
+35,226
New +$394K ﹤0.01% 2329
2020
Q4 		– Sell
-49,919
Closed -$738K – 3254
2020
Q3 		$738K Buy
49,919
+38,069
+321% +$713K 0.01% 1168
2020
Q2 		$249K Buy
+11,850
New +$304K ﹤0.01% 1713
2019
Q4 		– Sell
-49,622
Closed -$967K – 2790
2019
Q3 		$967K Sell
49,622
-6,439
-11% -$130K 0.01% 1263
2019
Q2 		$915K Buy
56,061
+38,656
+222% +$783K 0.01% 1315
2019
Q1 		$395K Buy
+17,405
New +$441K ﹤0.01% 1612
2016
Q3 		– Sell
-12,300
Closed -$279K – 1248
2016
Q2 		$279K Buy
+12,300
New +$266K 0.02% 772

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Squarepoint's TBPH Position: Q2 2026 in Review

Squarepoint opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 17,762 shares worth $302K. The stake represents ﹤0.01% of the portfolio and ranks #3800 among its holdings. This is a return to the name: Squarepoint previously reported a position in TBPH as recently as Q4 2025.

Squarepoint first reported a position in TBPH in Q2 2016 and has held it in 22 quarters since. The position peaked at $1.26M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Squarepoint held 17,762 shares of Theravance Biopharma worth $302K as of Q2 2026.
  • Theravance Biopharma was a new Squarepoint position in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3800 holding.
  • Squarepoint first reported a position in Theravance Biopharma in Q2 2016 and has held it in 22 quarters since.
  • Squarepoint's Theravance Biopharma position peaked at $1.26M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.